ZBIO (Zenas BioPharma) ROE % Adjusted to Book Value: -30.88% (As of Mar. 2026)


ZBIO Zenas BioPharma Inc ZBIO
12 GF Score
Price $26.90
! 1 Warning Sign
View Full Analysis

What is Zenas BioPharma ROE % Adjusted to Book Value?

Zenas BioPharma ZBIO -2.70% 12 ROE % Adjusted to Book Value is -30.88% as of Mar. 2026. GuruFocus rates ZBIO with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Zenas BioPharma's ROE % for the quarter that ended in Mar. 2026 was -112.10%. Zenas BioPharma's PB Ratio for the quarter that ended in Mar. 2026 was 3.63. Zenas BioPharma's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -30.88%.

Zenas BioPharma ROE % Adjusted to Book Value Related Terms

Zenas BioPharma ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Zenas BioPharma's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Zenas BioPharma ROE % Adjusted to Book Value Chart

Zenas BioPharma Annual Data
Trend Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
0.00 0.00 -329.08 -16.67

Zenas BioPharma Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -38.80 -46.91 -19.81 -53.68 -30.88

ZBIO vs AKTS, MLTX, FTRE: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Zenas BioPharma's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zenas BioPharma ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zenas BioPharma's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Zenas BioPharma's ROE % Adjusted to Book Value falls into.


ZBIO
12GF Score
Zenas BioPharma Inc ZBIO
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Zenas BioPharma ROE % Adjusted to Book Value Calculation

Zenas BioPharma's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-136.22% / 8.17
=-16.67%

Zenas BioPharma's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-112.10% / 3.63
=-30.88%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -30.88% mean?
Zenas BioPharma (ZBIO) has a ROE % Adjusted to Book Value of -30.88% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Zenas BioPharma and its competitors.
Is Zenas BioPharma's ROE % Adjusted to Book Value too high?
Zenas BioPharma's current ROE % Adjusted to Book Value is -30.88%. Overall, Zenas BioPharma has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Zenas BioPharma's ROE % Adjusted to Book Value compare to AKTS and MLTX?
Zenas BioPharma's ROE % Adjusted to Book Value of -30.88% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Zenas BioPharma and its competitors. Zenas BioPharma's current ROE % Adjusted to Book Value is -30.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zenas BioPharma stock overvalued right now?
Zenas BioPharma (ZBIO) has a current ROE % Adjusted to Book Value of -30.88%. The current ROE % Adjusted to Book Value is -30.88%. Zenas BioPharma's overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Zenas BioPharma (ZBIO), the current ROE % Adjusted to Book Value is -30.88% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Zenas BioPharma Business Description

Address 852 Winter Street, Suite 250, Waltham, MA, USA, 02451
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.
12GF Score

Get the complete analysis for ZBIO

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.90
Price